Pylarify injections
Active Awarded Last action
- Contract number
- 36C24723F0136
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 7
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $3,384,527
Award facts
- Contract value 55% obligated
-
- $3,404,527.04 Current, with exercised options
- $6,159,067.04 Potential, with all options
- Completion date 77% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $918,180 | |
| Supplemental Agreement for work within scope | $433,046 | |
| Funding Only Action | -$56,913 | |
| Exercise an Option | $918,180 | |
| Supplemental Agreement for work within scope | -$664,326 | |
| Exercise an Option | $918,180 | |
| Original award | $918,180 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 7 (VISN 7) awarded a $6.16M delivery order to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., on December 15, 2022 for the supply of PYLARIFY Injections. This is a firm fixed-price contract with an ultimate completion date of December 14, 2027 and no set-aside designation. The product will be performed and delivered from the vendor's facility in North Billerica, Massachusetts. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer in patients. As a critical radiopharmaceutical, the product supports diagnostic imaging programs across VA medical centers within VISN 7.
This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), leveraging an existing indefinite delivery vehicle through which the VA can efficiently procure radiopharmaceutical products. Progenics Pharmaceuticals, as a subsidiary of parent company Lantheus Holdings, Inc., maintains significant federal contract vehicles with the VA and Defense Health Agency, with the company's Federal Supply Schedule contract carrying a $290M ceiling value through March 31, 2030. The delivery order structure allows VISN 7 to acquire essential medical imaging agents to support prostate cancer diagnostic capabilities across its veteran healthcare network.
Quick answers
Who was awarded contract 36C24723F0136?
36C24723F0136 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 7 (Veterans Health Administration) on December 15, 2022.
How much is contract 36C24723F0136 worth?
The government has obligated $3,384,527 on 36C24723F0136. Its current value, with exercised options, is $3,404,527. Its potential value, with all options, is $6,159,067.
Is contract 36C24723F0136 an order under another contract?
Yes. 36C24723F0136 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24723F0136 competed?
The extent of competition for 36C24723F0136 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award